HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

Biotech Giants' Profit Surge: A Decade of Growth

__timestampArrowhead Pharmaceuticals, Inc.HUTCHMED (China) Limited
Wednesday, January 1, 201417500019764000
Thursday, January 1, 201538200067426000
Friday, January 1, 201615833359752000
Sunday, January 1, 20173140770965383000
Monday, January 1, 20181614232170165000
Tuesday, January 1, 201916879557744738000
Wednesday, January 1, 20208799206639457000
Friday, January 1, 202113828700097894000
Saturday, January 1, 2022232810000115306000
Sunday, January 1, 2023240735000453552000
Monday, January 1, 20243551000
Loading chart...

In pursuit of knowledge

A Tale of Two Innovators: HUTCHMED and Arrowhead Pharmaceuticals

In the dynamic world of biotechnology, HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc. have carved distinct paths. Over the past decade, HUTCHMED has consistently demonstrated robust growth, with its gross profit peaking at an impressive $453 million in 2023, marking a staggering 1300% increase since 2014. This growth underscores HUTCHMED's strategic advancements in the Chinese pharmaceutical market.

Conversely, Arrowhead Pharmaceuticals has shown a more volatile trajectory. Despite a modest start in 2014, Arrowhead's gross profit surged to $241 million by 2023, reflecting a remarkable 137,000% growth. This leap highlights Arrowhead's innovative strides in RNA interference therapeutics.

While both companies have faced challenges, including missing data in recent years, their financial narratives reveal the resilience and potential of biotech firms in shaping the future of medicine.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025